How Mounjaro and Zepbound work — mechanism comparison
Mounjaro and Zepbound contain the same active ingredient (tirzepatide), so they work through the same molecular pathway. The differences are in dosing, FDA-approved indications, and labeling — not in how the drug acts on your body. Both bind to GLP-1 receptors, slow gastric emptying, increase insulin secretion in response to meals, and signal satiety to the brain.
This shared mechanism matters because it determines: efficacy (how much weight loss / blood-sugar control you can expect), side-effect profile, dosing schedule, and which patients may benefit most. Read more in our Mounjaro mechanism guide and Zepbound mechanism guide.
Efficacy head-to-head
In their respective pivotal trials, mean body-weight reduction reached:
- Mounjaro: 22.5% at 72 weeks (trial: SURMOUNT-1)
- Zepbound: 22.5% at 72 weeks (trial: SURMOUNT-1)
The two are effectively equivalentin trial-mean efficacy (<1% difference). Individual response variability is far larger than this between-drug difference.
Side-by-side radar: Mounjaro vs Zepbound
Editorial scoring across 5 dimensions, overlaid. Higher area = better overall fit.
| Axis | Mounjaro | Zepbound |
|---|---|---|
| Efficacy | 10 | 10 |
| Convenience | 9 | 9 |
| Affordability | 5 | 5 |
| Tolerance | 6 | 6 |
| Evidence | 6 | 6 |
Higher score = better on that axis. Editorial scoring; not a substitute for prescriber judgment.
Side effects compared
Both drugs share the GLP-1 class side-effect profile — primarily gastrointestinal (nausea, diarrhea, constipation, vomiting) in early treatment, fading as the body adapts. Both carry the FDA boxed warning for thyroid C-cell tumors and contraindications for personal/family history of medullary thyroid carcinoma.
Comparative trial data on common side effects (rates may differ from real-world):
- Nausea rate (Mounjaro): 31%
- Nausea rate (Zepbound): 31%
- Diarrhea rate (Mounjaro): 22%
- Diarrhea rate (Zepbound): 22%
Patients who tolerate one GLP-1 well often (but not always) tolerate another. Switching between class members typically requires re-titration regardless of prior tolerability. See full side-effect breakdowns for Mounjaro and Zepbound.
Dosing schedule comparison
Both medications use step-up titration to minimize side effects, but the schedule details differ:
Mounjaro
- Week 1–4: 2.5 mg
- Week 5–8: 5 mg
- Week 9+: 7.5–15 mg
- Maintenance: Up to 15 mg
Zepbound
- Week 1–4: 2.5 mg
- Week 5–8: 5 mg
- Week 9+: 7.5–15 mg
- Maintenance: Up to 15 mg
See full titration guides for Mounjaro dosing and Zepbound dosing.
Cost comparison
Cost differences between Mounjaro and Zepbound depend on insurance coverage, manufacturer savings programs, and partner-network pricing — not just retail price.
- Average retail price (Mounjaro): $1135/month
- Average retail price (Zepbound): $1086/month
- Mounjaro savings card: as low as $25/month for eligible commercial-insured
- Zepbound savings card: as low as $25/month for eligible commercial-insured
For most patients, the actual out-of-pocket cost is driven by: (1) what your insurance formulary tier places Mounjaro vs Zepbound, (2) whether you qualify for manufacturer savings cards (commercial insurance only), and (3) telehealth partner network availability. Full cost breakdowns: Mounjaro cost guide · Zepbound cost guide.
Which one to choose — decision factors
There's no single «better» drug — the right choice depends on individual circumstances. The key decision factors:
Choose Mounjaro if…
- Your insurance covers it but not Zepbound
- Your prescriber has more experience with it
Choose Zepbound if…
- Your insurance covers it but not Mounjaro
- Your prescriber has more experience with it
Switching from Mounjaro to Zepbound (or vice versa)
Because Mounjaro and Zepbound contain the same active ingredient, switching between them is relatively simple — your prescriber can often transition you at the dose-equivalent point without re-titration. Common reasons to switch include insurance formulary changes, different FDA-approved indications, or different dose ranges (e.g., Wegovy goes higher than Ozempic; Zepbound and Mounjaro have different labeled indications despite identical active ingredient).
FAQ — Mounjaro vs Zepbound
Are Mounjaro and Zepbound the same drug?
Yes — both contain tirzepatide. They differ in FDA-approved indications, dose ranges, and labeling, but the active ingredient is identical.
Which is more effective for weight loss?
In separate pivotal trials, Zepbound produced 0.0 percentage points more weight loss than Mounjaro on average. However, these were separate trials with different populations — not head-to-head comparison. Individual response variability is also large. Most patients achieve clinically meaningful weight loss with either drug.
Can I take Mounjaro and Zepbound together?
No. Combining two GLP-1 receptor agonists provides no added benefit and dramatically increases side-effect risk. Standard practice is to switch between them, not combine.
Which has fewer side effects?
Side-effect profiles are broadly similar across GLP-1 medications — primarily GI effects that fade with adaptation. Individual tolerance varies. Trial data shows comparable rates of nausea, diarrhea, and other common effects between Mounjaro and Zepbound.
Will my insurance cover one but not the other?
Often yes. Insurance formularies are negotiated separately per drug — Mounjaro may be on Tier 2 of your plan while Zepbound is Tier 4 (or excluded). Check your formulary before assuming both are equally accessible.
Editorial comparison based on FDA prescribing information and published clinical data. Not a substitute for prescriber consultation. Full medical disclaimer.